AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Merus has 8.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Merus (merus.nl)
Merus is a high-substance biotech entity currently undergoing a ‘zombie site’ transition following its acquisition by Genmab. While its technical claims are granular and likely legitimate, the presence of consumer-style review schemas and the abandonment of its own pipeline tracking are significant BS indicators for an industry where precision and transparency are paramount.
Remove the review_count schema and any star-rating artifacts immediately to eliminate trust theatre signals. Update the homepage H1 and meta-description to reflect the Genmab acquisition to ensure semantic coherence. Replace the ‘Scientific Publications’ button with direct, numbered citations and outbound DOI links to clinical results. Add a ‘Leadership’ section with named experts and linked LinkedIn profiles or ORCID IDs to close the authority gap.
While the homepage and pipeline page are critically insufficient (under 400 characters), the About and Technology pages provide high information density. Headings like ‘Closing in on Cancer’ and ‘Every Day’ are 100% fluff, but the body text compensates with specific technical nouns such as ‘petosemtamab,’ ‘EGFR,’ ‘LGR5,’ and ‘Phase 3 registrational trials.’ The substance ratio is high once the user navigates past the hero sections.
A site without a coherent link graph forces AI to guess which pages matter. Reveal your real semantic graph and see how your domain is actually mapped by machine logic.
The homepage acts as a high-level signal for ‘Closing in on Cancer,’ which is substantiated by the sub-pages’ deep dives into antibody engineering. However, a significant drift occurs on the Pipeline page, where the company reveals it is ‘now part of Genmab,’ a transition not mentioned in the homepage H1 or hero text. This creates a disconnect between the brand’s independent ‘mission’ and its current corporate reality as a subsidiary.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
The site exhibits clear Trust Theatre patterns with review_count values of 2 and 3 appearing in the schema data across multiple pages despite having 0 proof_links_count. Displaying ‘reviews’ for a clinical-stage biotech firm is a common CMS artifact that functions as BS, as medical research outcomes are not measured via consumer star ratings. Bold claims regarding ‘encouraging single agent clinical activity’ lack direct, linked citations to ClinicalTrials.gov or peer-reviewed journals within the crawled text.
The ratio of evidence is respectable, with 8+ specific technical proof points identified across the sub-pages (e.g., target combinations, specific cancer indications, and trial phases). However, the absolute lack of outbound proof links (0 counted) forces the user to take these technical claims at face value, which is a significant proof-path deficiency. The ‘View Publications’ CTA is a signal of substance that requires external navigation to verify.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The brand avoids most commodity traps through its proprietary ‘Multiclonics,’ ‘Biclonics,’ and ‘Triclonics’ terminology, which are unique to their intellectual property. Industry cliches like ‘mission to close in on cancer’ and ‘passion to help patients’ are present but secondary to the technical value proposition. The template language is standard (About Us, Pipeline, Technology) but contains mostly unique, rather than boilerplate, body content.
Authority is primarily established through technical jargon and trial references rather than named human experts. The data reveals a lack of specific leadership or scientific board names (Person schema is missing), which creates an ‘anonymous corporate’ profile. The technical implementation is professional with clean JSON-LD, though the reliance on external Genmab links for current data indicates a loss of local site authority.
The marketing tone ‘Closing in on Cancer’ is a bold emotive claim, but it is backed by the mention of ‘Phase 3 registrational trials,’ which is the highest level of pre-market proof in this industry. The disconnect is minor, primarily existing in the gap between the ‘urgency’ claimed on the homepage and the reality of long-term clinical trial timelines. The transition to Genmab further complicates the ‘Our Pipeline’ performance claims.
Medical Devices, Pharma & Biotech BS: Merus (merus.nl)
The site strongly aligns with the Pharma & Biotech industry, specifically clinical-stage oncology. The presence of specific drug candidates like petosemtamab and detailed descriptions of bispecific antibody platforms (Multiclonics) confirms this classification.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The score of 32 is driven primarily by Trust and Proof deficiencies (Review counts vs Proof links) and the Semantic Drift caused by the Genmab acquisition disclosure being buried on a sub-page. The high technical specificity in the antibody descriptions prevents the score from reaching the 'Moderate BS' range.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 24, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Merus to view the most current version of their content and see directly what the company offers.